This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cameron, M L Articles by Perfect, J R Search for Related Content PubMed PubMed Citation Articles by Cameron, M L Articles by Perfect, J R

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1993 November; 37(11): 2449-2453

Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1.

Department of Medicine, Duke University Medical Center, Durham, North Carolina.

ABSTRACT

Yeast strains isolated from the oropharynx of 87 consecutive patients infected with human immunodeficiency virus type 1 were examined for in vitro susceptibility to fluconazole. Candida albicans was isolated from 73 patients. Fifty-one patients had received antifungal therapy in the month preceding the yeast infection. Thirty-two patients had symptomatic oropharyngeal candidiasis. The MICs were correlated with azole use and with clinical symptoms and signs. Although there is overlap between groups, in vitro testing identified a large group of patients for whose yeast isolates the fluconazole MICs were high and who remained symptomatic while receiving azole therapy. This study supports the ability of in vitro testing to predict the clinical outcome of mucosal fungal infections. The study also demonstrates that azole resistance of oropharyngeal yeasts is a common problem in patients infected with human immunodeficiency virus type 1 and that this azole resistance has clinical relevance.

This article has been cited by other articles:

• Pfaller, M. A., Diekema, D. J., Sheehan, D. J. (2006). Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing. Clin. Microbiol. Rev. 19: 435-447 [Abstract] [Full Text]  
• Kojima, K., Bahn, Y.-S., Heitman, J. (2006). Calcineurin, Mpk1 and Hog1 MAPK pathways independently control fludioxonil antifungal sensitivity in Cryptococcus neoformans.. Microbiology 152: 591-604 [Abstract] [Full Text]  
• Dorrell, L, Edwards, A (2002). Vulvovaginitis due to fluconazole resistant Candida albicans following self treatment with non-prescribed triazoles. Sex. Transm. Infect. 78: 308-309 [Full Text]  
• Tsuchimori, N., Hayashi, R., Kitamoto, N., Asai, K., Kitazaki, T., Iizawa, Y., Itoh, K., Okonogi, K. (2002). In Vitro and In Vivo Antifungal Activities of TAK-456, a Novel Oral Triazole with a Broad Antifungal Spectrum. Antimicrob. Agents Chemother. 46: 1388-1393 [Abstract] [Full Text]  
• Woyke, T., Pettit, G. R., Winkelmann, G., Pettit, R. K. (2001). In Vitro Activities and Postantifungal Effects of the Potent Dolastatin 10 Derivative Auristatin PHE. Antimicrob. Agents Chemother. 45: 3580-3584 [Abstract] [Full Text]  
• Marchetti, O., Majcherczyk, P. A., Glauser, M. P., Bille, J., Moreillon, P., Sanglard, D. (2001). Sensitive Bioassay for Determination of Fluconazole Concentrations in Plasma Using a Candida albicans Mutant Hypersusceptible to Azoles. Antimicrob. Agents Chemother. 45: 696-700 [Abstract] [Full Text]  
• Lee, S.-C., Fung, C.-P., Huang, J.-S., Tsai, C.-J., Chen, K.-S., Chen, H.-Y., Lee, N., See, L.-C., Shieh, W.-B. (2000). Clinical Correlates of Antifungal Macrodilution Susceptibility Test Results for Non-AIDS Patients with Severe Candida Infections Treated with Fluconazole. Antimicrob. Agents Chemother. 44: 2715-2718 [Abstract] [Full Text]  
• Cacciapuoti, A., Loebenberg, D., Corcoran, E., Menzel, F. Jr., Moss, E. L. Jr., Norris, C., Michalski, M., Raynor, K., Halpern, J., Mendrick, C., Arnold, B., Antonacci, B., Parmegiani, R., Yarosh-Tomaine, T., Miller, G. H., Hare, R. S. (2000). In Vitro and In Vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, against Aspergillus and Candida. Antimicrob. Agents Chemother. 44: 2017-2022 [Abstract] [Full Text]  
• Rocco, T. R., Reinert, S. E., Simms, H. H. (2000). Effects of Fluconazole Administration in Critically Ill Patients: Analysis of Bacterial and Fungal Resistance. Arch Surg 135: 160-165 [Abstract] [Full Text]  
• Cruz, M. C., Del Poeta, M., Wang, P., Wenger, R., Zenke, G., Quesniaux, V. F. J., Movva, N. R., Perfect, J. R., Cardenas, M. E., Heitman, J. (2000). Immunosuppressive and Nonimmunosuppressive Cyclosporine Analogs Are Toxic to the Opportunistic Fungal Pathogen Cryptococcus neoformans via Cyclophilin-Dependent Inhibition of Calcineurin. Antimicrob. Agents Chemother. 44: 143-149 [Abstract] [Full Text]  
• Del Poeta, M., Chen, S.-F., Von Hoff, D., Dykstra, C. C., Wani, M. C., Manikumar, G., Heitman, J., Wall, M. E., Perfect, J. R. (1999). Comparison of In Vitro Activities of Camptothecin and Nitidine Derivatives against Fungal and Cancer Cells. Antimicrob. Agents Chemother. 43: 2862-2868 [Abstract] [Full Text]  
• Martin, M. V. (1999). The use of fluconazole and itraconazole in the treatment of Candida albicans infections: a review. J Antimicrob Chemother 44: 429-437 [Abstract] [Full Text]  
• Rimaroli, C., Bruzzese, T. (1998). In Vitro Activity of a New Polyene, SPA-S-843, against Yeasts. Antimicrob. Agents Chemother. 42: 3012-3013 [Abstract] [Full Text]  
• Del Poeta, M., Schell, W. A., Dykstra, C. C., Jones, S., Tidwell, R. R., Czarny, A., Bajic, M., Bajic, M., Kumar, A., Boykin, D., Perfect, J. R. (1998). Structure-In Vitro Activity Relationships of Pentamidine Analogues and Dication-Substituted Bis-Benzimidazoles as New Antifungal Agents. Antimicrob. Agents Chemother. 42: 2495-2502 [Abstract] [Full Text]  
• Del Poeta, M., Schell, W. A., Dykstra, C. C., Jones, S. K., Tidwell, R. R., Kumar, A., Boykin, D. W., Perfect, J. R. (1998). In Vitro Antifungal Activities of a Series of Dication-Substituted Carbazoles, Furans, and Benzimidazoles. Antimicrob. Agents Chemother. 42: 2503-2510 [Abstract] [Full Text]  
• White, T. C., Marr, K. A., Bowden, R. A. (1998). Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance. Clin. Microbiol. Rev. 11: 382-402 [Abstract] [Full Text]  
• Revankar, S., Kirkpatrick, W., McAtee, R., Fothergill, A., Redding, S., Rinaldi, M., Patterson, T. (1998). Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method [In Process Citation]. J. Clin. Microbiol. 36: 153-156 [Abstract] [Full Text]  
• Powderly, W. G., Finkelstein, D. M., Feinberg, J., Frame, P., He, W., van der Horst, C., Koletar, S. L., Eyster, M. E., Carey, J., Waskin, H., Hooton, T. M., Hyslop, N., Spector, S. A., Bozzette, S. A., The NIAID AIDS Clinical Trials Group, (1995). A Randomized Trial Comparing Fluconazole with Clotrimazole Troches for the Prevention of Fungal Infections in Patients with Advanced Human Immunodeficiency Virus Infection. NEJM 332: 700-705 [Abstract] [Full Text]  
• Como, J. A., Dismukes, W. E. (1994). Oral Azole Drugs as Systemic Antifungal Therapy. NEJM 330: 263-272 [Full Text]